Bridgebio Oncology Therapeutics, Inc. (BBOT)
4.665
-0.10
(-2.20%)
USD |
NASDAQ |
Sep 21, 11:54
Bridgebio Oncology Therapeutics Net Income (Quarterly) : -56.45M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -56.45M |
| March 31, 2026 | -42.11M |
| December 31, 2025 | -38.80M |
| September 30, 2025 | -44.76M |
| June 30, 2025 | -28.44M |
| March 31, 2025 | -22.06M |
| Date | Value |
|---|---|
| December 31, 2024 | -19.69M |
| September 30, 2024 | -17.32M |
| June 30, 2024 | 2.212M |
| March 31, 2024 | 1.100M |
| December 31, 2023 | -0.0417M |
| December 31, 2022 | -0.0035M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 56.45M |
| EPS Diluted (Quarterly) | -705.20 |
| Enterprise Value | 158.95M |
| Earnings Yield | -26.43K% |
| Normalized Earnings Yield | -26427.17 |